"Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis" by Vibeke Strand

Article

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis

Journal of Comparative Effectiveness Research (2019)

Vibeke Strand, Biopharmaceutical Consultant, 306 Ramona Road, Portola Valley, CA 94028, USA
Iain McInnes, University of Glasgow
Philip Mease, University of Washington
Peter Nash, University of Queensland
Howard Thom, University of Bristol
Chrysostomos Kalyvas, Mapi, an ICON plc company, De Molen 84, 3995 AX, Houten, Netherlands (address at the time that the study was conducted)
Matthias Hunger, Mapi, an ICON plc company, Konrad-Zuse-Platz 11, 81829 Munich, Germany
Kunal Gandhi, Novartis
Luminita Pricop, Novartis
Steffen Jugl, Novartis
Ernest Choy, Cardiff University

Link

Disciplines

Publication Date

February 26, 2019

DOI

10.2217/cer-2018-0141

Citation Information

Vibeke Strand, Iain McInnes, Philip Mease, Peter Nash, et al.. "Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis" Journal of Comparative Effectiveness Research (2019)
Available at: http://works.bepress.com/philip-mease/313/